Médecine

Paramédical

Autres domaines


S'abonner

Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo - 15/11/14

Doi : 10.1016/j.jaad.2014.07.050 
Andrea Paradisi, MD, PhD a, , Stefano Tabolli, MD, MPH a, Biagio Didona, MD b, Luciano Sobrino c, Nicoletta Russo, MD d, Damiano Abeni, MD, MPH a
a Health Services Research Unit, Istituto Dermopatico dell'Immacolata, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy 
b First Dermatological Clinic, Istituto Dermopatico dell'Immacolata, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy 
c Hospital Information System, Istituto Dermopatico dell'Immacolata, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy 
d Medical Direction, Istituto Dermopatico dell'Immacolata, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy 

Reprint requests: Andrea Paradisi, MD, PhD, Health Services Research Unit, Istituto Dermopatico dell'Immacolata, Istituto di Ricovero e Cura a Carattere Scientifico, Via dei Monti di Creta, 104, I-00167 Rome, Italy.

Abstract

Background

Genetic findings suggesting a lower susceptibility to melanoma in patients with vitiligo are supported by recent clinical studies. Nonmelanoma skin cancer (NMSC) has also been studied, but mainly in small samples, and with conflicting results.

Objective

We sought to study the relative risk (RR) of melanoma and NMSC in patients with vitiligo compared with that in patients seen for vascular surgery.

Methods

The frequency of melanoma and NMSC was compared between patients with vitiligo and patients seen for vascular surgery. Occurrence of skin cancer was compared by computing RR and modeled using multiple logistic regression.

Results

Overall, the crude RR for melanoma was 0.24 (95% confidence interval [CI] 0.13-0.45) in patients with vitiligo compared with those with a nondermatologic condition (occurrence 1.1‰, 95% CI 0.5‰-2.0‰ in patients with vitiligo and occurrence 4.5‰, 95% CI 3.8‰-5.4‰ in the control cohort). The crude RR for NMSC was 0.19 (95% CI 0.14-0.17) and the occurrence was 3.8‰ (95% CI 2.7‰-5.2‰) among patients with vitiligo and 19.6‰ (95% CI 18.0‰-21.4‰) in control subjects. Patients with vitiligo who underwent phototherapy had a markedly higher risk of both cancers.

Conclusions

In our large study, patients with vitiligo have a decreased risk of developing skin neoplasms, even considering that a larger proportion in this patient group is exposed to higher levels of ultraviolet radiation.

Le texte complet de cet article est disponible en PDF.

Key words : cutaneous melanoma, nonmelanoma skin cancer, vitiligo

Abbreviations used : CI, NMSC, PUVA, RR, UV


Plan


 This study was supported, in part, by the Italian Ministry of Health, Rome, Italy, Progetto Ricerca Corrente 2012–RC5.3.
 Conflicts of interest: None declared.


© 2014  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 71 - N° 6

P. 1110-1116 - décembre 2014 Retour au numéro
Article précédent Article précédent
  • Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
  • Martina Sanlorenzo, Aditi Choudhry, Igor Vujic, Christian Posch, Kim Chong, Katia Johnston, Melissa Meier, Simona Osella-Abate, Pietro Quaglino, Adil Daud, Alain Algazi, Klemens Rappersberger, Susana Ortiz-Urda
| Article suivant Article suivant
  • Clinical presentation, immunopathology, and treatment of juvenile-onset mycosis fungoides: A case series of 34 patients
  • Scarlett Boulos, Reena Vaid, Tariq N. Aladily, Doina S. Ivan, Rakhshandra Talpur, Madeleine Duvic

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

;

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.